Related stories
Eli Lilly’s Retatrutide Cuts Knee Osteoarthritis Pain by Up to 75.8% in Phase 3 Trial
A Phase 3 trial reported that retatrutide cut knee osteoarthritis pain by up to 75.8%.
L impact | EQUITY | Nov 05, 2026, 11:50 AM UTC
Eli Lilly reports retatrutide reduced knee osteoarthritis pain in Phase 3
M impact | EQUITY | Nov 05, 2026, 11:50 AM UTC
Eli Lilly Reports Retatrutide Reduced Knee Osteoarthritis Pain in Phase 3 Study
Eli Lilly reported that retatrutide reduced knee osteoarthritis pain in a Phase 3 study.
M impact | EQUITY | Nov 05, 2026, 11:50 AM UTC
Becton Dickinson Fiscal Q4 Earnings Snapshot
M impact | EQUITY | Nov 05, 2026, 11:50 AM UTC
Tapestry Sees Q2 Revenue Growth of About 5% to 6%
Tapestry expects second-quarter revenue to grow about 5% to 6% year over year on a constant-currency basis.
M impact | EQUITY | Nov 05, 2026, 11:50 AM UTC
Cohere CEO Says IPO Timing Remains Uncertain Despite Revenue Growth
Cohere’s chief executive said the Canadian AI company’s timeline for going public remains uncertain. The company’s revenue is described as surging.
M impact | EQUITY | Nov 05, 2026, 11:49 AM UTC